These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 17322895)

  • 1. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
    Trivedi CM; Luo Y; Yin Z; Zhang M; Zhu W; Wang T; Floss T; Goettlicher M; Noppinger PR; Wurst W; Ferrari VA; Abrams CS; Gruber PJ; Epstein JA
    Nat Med; 2007 Mar; 13(3):324-31. PubMed ID: 17322895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
    Kee HJ; Eom GH; Joung H; Shin S; Kim JR; Cho YK; Choe N; Sim BW; Jo D; Jeong MH; Kim KK; Seo JS; Kook H
    Circ Res; 2008 Nov; 103(11):1259-69. PubMed ID: 18849323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.
    Eom GH; Cho YK; Ko JH; Shin S; Choe N; Kim Y; Joung H; Kim HS; Nam KI; Kee HJ; Kook H
    Circulation; 2011 May; 123(21):2392-403. PubMed ID: 21576649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8.
    Yan M; Chen C; Gong W; Yin Z; Zhou L; Chaugai S; Wang DW
    Cardiovasc Res; 2015 Mar; 105(3):340-52. PubMed ID: 25504627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
    Trivedi CM; Lu MM; Wang Q; Epstein JA
    J Biol Chem; 2008 Sep; 283(39):26484-9. PubMed ID: 18625706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway.
    Shang L; Pin L; Zhu S; Zhong X; Zhang Y; Shun M; Liu Y; Hou M
    Chem Biol Interact; 2019 Jul; 307():21-28. PubMed ID: 31009642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
    Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
    Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.
    Zhang CL; McKinsey TA; Chang S; Antos CL; Hill JA; Olson EN
    Cell; 2002 Aug; 110(4):479-88. PubMed ID: 12202037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness.
    Zhu W; Trivedi CM; Zhou D; Yuan L; Lu MM; Epstein JA
    Circ Res; 2009 Dec; 105(12):1240-7. PubMed ID: 19875726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
    Sugden PH; Fuller SJ; Weiss SC; Clerk A
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S137-53. PubMed ID: 18204489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
    Yoon S; Kook T; Min HK; Kwon DH; Cho YK; Kim M; Shin S; Joung H; Jeong SH; Lee S; Kang G; Park Y; Kim YS; Ahn Y; McMullen JR; Gergs U; Neumann J; Kim KK; Kim J; Nam KI; Kim YK; Kook H; Eom GH
    Exp Mol Med; 2018 Jul; 50(7):1-14. PubMed ID: 30050113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling.
    Tang Q; Cai J; Shen D; Bian Z; Yan L; Wang YX; Lan J; Zhuang GQ; Ma WZ; Wang W
    J Mol Med (Berl); 2009 Mar; 87(3):249-60. PubMed ID: 19096818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy.
    van de Schans VA; van den Borne SW; Strzelecka AE; Janssen BJ; van der Velden JL; Langen RC; Wynshaw-Boris A; Smits JF; Blankesteijn WM
    Hypertension; 2007 Mar; 49(3):473-80. PubMed ID: 17210832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling.
    Ying H; Xu MC; Tan JH; Shen JH; Wang H; Zhang DF
    Int J Mol Sci; 2014 Nov; 15(11):20240-53. PubMed ID: 25380525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
    Raghunathan S; Goyal RK; Patel BM
    Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.
    Kook H; Lepore JJ; Gitler AD; Lu MM; Wing-Man Yung W; Mackay J; Zhou R; Ferrari V; Gruber P; Epstein JA
    J Clin Invest; 2003 Sep; 112(6):863-71. PubMed ID: 12975471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2.
    Yoon S; Kim M; Min HK; Lee YU; Kwon DH; Lee M; Lee S; Kook T; Joung H; Nam KI; Ahn Y; Kim YK; Kim J; Park WJ; McMullen JR; Eom GH; Kook H
    Cardiovasc Res; 2019 Nov; 115(13):1850-1860. PubMed ID: 30596969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways.
    Li HL; Wang AB; Huang Y; Liu DP; Wei C; Williams GM; Zhang CN; Liu G; Liu YQ; Hao DL; Hui RT; Lin M; Liang CC
    Free Radic Biol Med; 2005 Jan; 38(2):243-57. PubMed ID: 15607907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.